Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Image Integration to Identify Histologic and Electroanatomic Ventricular Scar: A Clinicopathological Study Comparing 2 Image Integration Systems.

JACC. Clinical electrophysiology·2026

Same author

Device encapsulated MSCs for adaptive secretome therapy to effectively target ischaemic heart injury.

Stem cell research & therapy·2025

Same author

Human Hearts Intrinsically Increase Cardiomyocyte Mitosis After Myocardial Infarction.

Circulation research·2025

Same author

Immune regulation following allogeneic iPSC-derived cardiomyocyte transplantation in non-human primates.

Cardiovascular research·2025

Same author

Platelet derived growth factor-AB modulates post-infarct myocardium leading to extended improvement in cardiac function.

NPJ Regenerative medicine·2025

Same author

Comparison of Extrastimulus Pacing Strategies for the Detection of Arrhythmogenic Substrate for Ventricular Tachycardia: Insights From a Porcine Ischemia-Reperfusion Injury Model.

Circulation. Arrhythmia and electrophysiology·2025

Search research articles

Related Experiment Video

Updated: May 21, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Cell therapy for left ventricular dysfunction: an overview for cardiac clinicians.

James J H Chong¹

¹Center for Cardiovascular Biology, University of Washington, Seattle, WA 98109, USA. jamesc1@uw.edu

Heart, Lung & Circulation

|June 5, 2012

Summary

Cell therapies offer promising treatments for heart failure, potentially reducing global healthcare costs. Research explores various cell types, including bone marrow mononuclear cells and stem cells, for cardiac regeneration.

More Related Videos

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 21, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Published on: January 7, 2019

Area of Science:

Cardiovascular regeneration
Cell-based therapies
Regenerative medicine

Background:

Heart failure presents a significant global health burden with high morbidity and costs.
Developing effective cell therapies is crucial for cardiovascular regeneration.
Numerous cell types are under investigation for cardiac repair, complicating the field.

Purpose of the Study:

To provide an overview of cell types being explored for cardiac cell therapy.
To summarize the current landscape of clinical trials and research in cardiac regeneration.
To highlight the translational progress and future potential of cell-based cardiac repair.

Main Methods:

Review of existing literature on cell types for cardiac therapy.
Analysis of cell populations from extra-cardiac and cardiac sources.
Examination of ongoing and completed clinical trials and preclinical studies.

Main Results:

Key cell types include skeletal myoblasts, bone marrow mononuclear cells, mesenchymal stem cells, and various cardiac stem cell populations.
Bone marrow mononuclear cells are the most studied, with ongoing large clinical trials.
Early phase trials are investigating mesenchymal stem cells and cardiac stem cells, while embryonic stem cell therapies are in large animal models.

Conclusions:

Significant translational progress has been made in cardiac cell therapy research.
Multiple cell products and protocols for cardiac repair are anticipated in the near future.
Continued investigation into diverse cell sources is driving innovation in cardiovascular regeneration.